key: cord-0714979-l3cisx2n
authors: Röltgen, Katharina; Nielsen, Sandra C.A.; Silva, Oscar; Younes, Sheren F.; Maxim Zaslavsky,; Costales, Cristina; Yang, Fan; Wirz, Oliver F.; Solis, Daniel; Hoh, Ramona A.; Wang, Aihui; Arunachalam, Prabhu S.; Colburg, Deana; Zhao, Shuchun; Haraguchi, Emily; Lee, Alexandra S.; Shah, Mihir M.; Manohar, Monali; Chang, Iris; Gao, Fei; Mallajosyula, Vamsee; Li, Chunfeng; Liu, James; Shoura, Massa J.; Sindher, Sayantani B.; Parsons, Ella; Dashdorj, Naranjargal J.; Dashdorj, Naranbaatar D.; Monroe, Robert; Serrano, Geidy E.; Beach, Thomas G.; Chinthrajah, R. Sharon; Charville, Gregory W.; Wilbur, James L.; Wohlstadter, Jacob N.; Davis, Mark M.; Pulendran, Bali; Troxell, Megan L.; Sigal, George B.; Natkunam, Yasodha; Pinsky, Benjamin A.; Nadeau, Kari C.; Boyd, Scott D.
title: Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination
date: 2022-01-25
journal: Cell
DOI: 10.1016/j.cell.2022.01.018
sha: dbe4605ec00ea1ce4024b5080f63fc35dc83a0d4
doc_id: 714979
cord_uid: l3cisx2n

During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including 3rd dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and Gam-COVID-Vac) or inactivated viral (BBIBP-CorV) vaccines. We analyzed human lymph nodes after infection or mRNA vaccination for correlates of serological differences. Antibody breadth against viral variants is less after infection compared to all vaccines evaluated, but improves over several months. Viral variant infection elicits variant-specific antibodies, but prior mRNA vaccination imprints serological responses toward Wuhan-Hu-1 rather than variant antigens. In contrast to disrupted germinal centers (GCs) in lymph nodes during infection, mRNA vaccination stimulates robust GCs containing vaccine mRNA and spike antigen up to 8 weeks post-vaccination in some cases. SARS-CoV-2 antibody specificity, breadth and maturation are affected by imprinting from exposure history, and distinct histological and antigenic contexts in infection compared to vaccination.

was seen in a second, independent validation cohort (Stanford cohort 2) of predominantly mildly 195 ill COVID-19 patients. Greater Wuhan-Hu-1 to variant RBD IgG binding ratios were found in 196

week 2 to 3, month 1, month 3, and month 7 in infected patients compared to vaccinees (Figures 197 S4A and S4B) , with improvement in variant recognition over time in the infected patients. Notably, 198 the increased breadth of vaccinee IgG compared to COVID-19 patient IgG binding to viral variant 199 antigens was greatest for RBD, the main target of neutralizing antibodies, and was decreased or 200 not detected when whole spike antigens were tested ( Figure S4C ). Functional blocking of ACE2 201 binding to RBD was concordant with the RBD-specific IgG concentrations measured in these 202 populations ( Figures S4A and S4D) . 203 204

Several including mRNA, and inactivated virus vaccines, 207 have been approved for use internationally. Varying efficacy and antibody responses from the 208 vaccines have been reported (Baden et al., 2021; Dashdorj et al., 2021a Dashdorj et al., , 2021b Polack et al., 2020; 209 Sadoff et al., 2021; Voysey et al., 2021) . We compared IgG responses in Stanford COVID-19 210 cohort 2 patients and BNT162b2 vaccinees to those of participants in a Mongolian observational 211 study deploying four different COVID-19 vaccines: the mRNA vaccine BNT162b2; adenoviral 212 vectored vaccines ChAdOx1-S (AstraZeneca) and Gam-COVID-Vac (Sputnik V); and an alum-213 adjuvanted, inactivated viral vaccine BBIBP-CorV (Sinopharm). RBD-specific IgG 214 concentrations for Wuhan-Hu-1 and all viral variants measured (Epsilon, Kappa, B.1.526.2, Delta, 215 Alpha, Eta/Iota, Gamma, P.3, and Beta) differed greatly between vaccine groups, with BNT162b2 216 eliciting the highest antibody levels, followed by AstraZeneca, Sputnik V, and Sinopharm 217 vaccination ( Figure 4A ). IgG concentration differences between vaccines were significant for most 218 viral variant RBDs. Stanford BNT162b2 vaccinees compared to Mongolian BNT162b2 vaccinees 219 had higher IgG concentrations at early time points, likely due to differences in timing of sample 220 collection (Stanford day 28 and day 90; Mongolian participants variable time points before 1-221 month and 3-months) ( Figure 4A ). Despite the different vaccine compositions and magnitudes of 222 antibody responses, all four vaccines elicited IgG with relatively greater breadth of viral variant 223 RBD binding compared to that of infected patients ( Figure 4B ). 224 225

Immune imprinting, a phenomenon in which primary exposure to an antigen forms epitope-228 specific B cell memory and affects future B cell and antibody responses against variant epitopes, 229 has been studied in influenza infection and vaccination. COVID-19 patients and BNT162b2 230 vaccinees who were only exposed to Wuhan-Hu-1 antigens in this study exhibit a consistent 231 hierarchy in IgG binding concentrations to the different SARS-CoV-2 variant RBDs relative to the 232 Wuhan-Hu-1 RBD, decreasing from Epsilon, Kappa, B.1.526.2, Delta, Alpha, Eta/Iota, Gamma, 233 P.3, to Beta ( Figure S5A ). To test for imprinting of the serological response to variant RBDs, we 234 first analyzed the ratios of Wuhan-Hu-1 to variant RBD IgG concentrations in COVID-19 patients 235 who were infected with Alpha or Delta variants, confirmed by allele-specific RT-qPCR testing or 236 viral sequencing. IgG from Alpha or Delta variant-infected patients with no history of COVID-19 237 vaccination or prior SARS-CoV-2 infection preferentially bound Alpha and Delta variant RBDs, 238 respectively, compared to Wuhan-Hu-1 RBD ( Figure 5A , upper panels). Delta infection also 239 elicited higher IgG concentrations to other variant RBDs containing L452R such as Epsilon and 240 Kappa, compared to Wuhan-Hu-1 ( Figure similar to those of individuals exposed to only Wuhan-Hu-1. We quantified the degree of 248 imprinting of IgG specificity by log-transforming the ratios of IgG binding to pairs of antigens (for 249 example, Wuhan-Hu-1 RBD compared to Delta RBD) for individual samples, then rescaling to 250 range from -100% to +100% corresponding to the maximal preference for each antigen observed 251 in other plasma specimens, including those from individuals exposed only to a single antigen 252 variant ( Figure 5B ). 253

CoV-2 mRNA vaccination 256

The differences in viral variant RBD IgG binding between SARS-CoV-2 infected patients and 257 recipients of the four COVID-19 vaccines suggest that the organization of the humoral immune 258 responses in secondary lymphoid tissues may differ between infection and vaccination, potentially 259 due to direct effects of the viral infection, differences in innate immune stimuli between 260 vaccination and infection, or the quantity or localization of viral antigens, among other 261 possibilities. Previous studies have revealed a loss of GCs and a reduction in BCL6 + GC B cells 262 in severe acute SARS-CoV-2 infection, raising the possibility that humoral responses may be 263 altered or subverted by the virus (Kaneko et al., 2020) . It is unclear whether draining LN immune 264 responses to SARS-CoV-2 infection in the lungs differ from those elicited in axillary LNs 265 following deltoid intramuscular mRNA vaccination. To compare GC architecture in response to 266 SARS-CoV-2 infection and vaccination, we obtained peribronchial LN tissues from six COVID-267 19 patients and three control autopsy cases as well as axillary LN core needle biopsies of seven 268 individuals vaccinated with mRNA-1273 or BNT162b2. Importantly, core needle biopsy sample 269 tissue volumes were suitable for assessment of LN histoarchitecture. Vaccinee axillary LN 270 biopsies were from the ipsilateral (same-side) arm vaccinated. Controls were thoracic LNs from 271 individuals who succumbed to pre-pandemic non-COVID-19 pneumonias, and contain GCs likely 272 due to ongoing adaptive immune responses elicited by other antigens. LN histology for COVID-273 19 patients and vaccinees was evaluated with 4-color co-detection by indexing (CODEX) 274 immunofluorescence analysis for CD20, CD3, BCL6 and CD21, which are markers of B cells, T 275 cells, GC B cells (or T follicular helper (Tfh) cells) and follicular dendritic cells, respectively 276 ( Figure 6A , Figure S6A ), as well as by single-color immunohistochemical stains for these markers 277 and the Tfh cell marker PD-1 ( Figure 6B ). GCs were poorly formed in the severely ill COVID-19 278 patient peribronchial LNs compared to the axillary LNs of vaccinees, with disrupted CD21+ 279 follicular dendritic cell networks and decreased BCL6 + cells (including GC B cells 

and PD-1 + cells (consistent with Tfh cells) within GCs ( Figures 6A -6E ). Disruption of CD21 + 281 follicular dendritic cell networks was seen in both primary and secondary follicles in LNs from 282 COVID-19 patients ( Figure S6B ). mRNA vaccination was associated with follicular hyperplasia 283 with fully developed GC architecture, including robust induction of GC B cells, Tfh cells and 284 extensive follicular dendritic cell networks ( Figures 6A and 6B) . 285 J o u r n a l P r e -p r o o f

The biodistribution, quantity and persistence of vaccine mRNA and spike antigen after 289 vaccination, and viral antigens after SARS-CoV-2 infection, are incompletely understood but are 290 likely to be major determinants of immune responses. We performed in situ hybridization with 291 control and SARS-CoV-2 vaccine mRNA-specific RNAScope probes in the core needle biopsies 292 of the ipsilateral axillary LNs that were collected 7-60 days after 2 nd dose of mRNA-1273 or 293

BNT162b2 vaccination, and detected vaccine mRNA collected in the GCs of LNs on day 7, 16, 294 and 37 post vaccination, with lower but still appreciable specific signal at day 60 . Only rare foci of vaccine mRNA were seen outside of GCs. Axillary LN core needle biopsies 296 of non-vaccinees (n = 3) and COVID-19 patient specimens were negative for vaccine probe 297 hybridization. Immunohistochemical staining for spike antigen in mRNA vaccinated patient LNs 298 varied between individuals, but showed abundant spike protein in GCs 16 days post-2 nd dose, with 299 spike antigen still present as late as 60 days post-2 nd dose. Spike antigen localized in a reticular 300 pattern around the GC cells, similar to staining for follicular dendritic cell processes ( Figure 7B ). 301 COVID-19 patient LNs showed lower quantities of spike antigen, but a rare GC had positive 302 staining ( Figure 7F ). Immunohistochemical staining for N antigen in peribronchial LN secondary 303 and primary follicles of COVID-19 patients (Figures 7F -7I) was positive in 5 of the 7 patients, 304 with a mean percentage of nucleocapsid-positive follicles of more than 25%. 305 306 Spike protein was detected in the plasma of 96% of the vaccinees at days 1-2 (median spike 307 concentration of 47 pg/mL) and in 63% at day 7 (median spike concentration of 1.7 pg/mL) after 308 the prime vaccine dose. In contrast, spike antigen detection after the vaccine boost on day 21 was 309 reduced, with half of the study participants being positive on day 1-2 (median spike concentration 310 of 1.2 pg/mL) and only one individual on day 7 post-boost ( Figure 7J ). We suspected that high 311 concentrations of spike-specific antibodies developed by vaccinees within the first 2 to 3 weeks 312 after the prime vaccine dose could impede detection of spike antigen by competing for spike 313 binding sites with the anti-spike reagent antibodies in the antigen assay. To test this hypothesis, 314

we added different concentrations of recombinant spike protein to spike-negative vaccinee plasma 315 samples collected on day 0 (n = 3) and day 28 (n = 3) after the prime vaccination. One of the positive developments amid the global calamity of the SARS-CoV-2 pandemic has 327 been the rapid design, production and deployment of a variety of vaccines, including remarkably 328 effective mRNA vaccines encoding the viral spike (Baden et al., 2021; Polack et al., 2020) . We 329 find that BNT162b2 vaccination produces IgG responses to spike and RBD at concentrations as 330 high as those of severely ill COVID-19 patients and follows a similar time course. Unlike infection, 331 which stimulates robust but short-lived IgM and IgA responses, vaccination shows a pronounced 332 bias for IgG production even at early time points. These responses were similar across the adult 333 age range in our study. The relative absence of IgM and IgA responses suggests a potent effect of 334 the vaccine formulation in driving early and extensive IgG class-switching, potentially as a result 335 of the reported T helper type 1-polarized CD4 + T cell responses stimulated by vaccine components 336 (Lederer et al., 2020; Lindgren et al., 2017; Pardi et al., 2018) . Our data demonstrate that vaccinee 337 plasma and saliva spike and RBD-specific IgG concentrations decrease from their peak values by 338 approximately 20-fold by 9 months after primary vaccination, but quickly exceed prior peak 339 concentrations in 7 to 8 days after boosting with a 3 rd vaccine dose. ChAdOx1-S responses highlights the overall similarity of correlate of protection results for spike-344 binding antibody and neutralizing antibody assays (Feng et al., 2021; Gilbert et al., 2022) . We 345 compared spike or RBD-binding antibody responses to Wuhan-Hu-1 SARS-CoV-2 neutralization 346 data in BNT162b2 vaccinees and confirmed the high correlation of these assay results, supporting 347 the interpretation that sensitive, precise and validated commercial multiplexed antigen-binding 348 assays with a wide dynamic range, such as the MSD ECL assays in this study, will be valuable in 349 providing standardized correlates of protection data for vaccines as the pandemic continues. 350

Particularly in the context of viral variants, it will be important to determine whether predictions 351 of vulnerability to infection or severe disease can be improved by adding data from other 352 immunological assays, including T cell measurements. antigen binding were greatest for the RBD, the target of most neutralizing antibodies, and were 363 diminished when full spike antigen with its greater number of non-neutralizing epitopes was tested. 364

These results, covering many clinically relevant viral variant antigens and several vaccine 365 modalities, are consistent with findings for RBD binding IgG in mRNA-1273 vaccinees compared 366 to infected patients (Greaney et al., 2021b) . Notably, COVID-19 patients with Alpha or Delta 367 variant infections display characteristic serological profiles specific to the RBD of the infecting 368 variant, indicating that SARS-CoV-2 variant serotyping may be useful for epidemiological studies 369 of populations to determine exposure to circulating SARS-CoV-2 variants. Both vaccinees and 370 COVID-19 patients exposed to Wuhan-Hu-1 antigens show the greatest decreases in antibody 371 binding to RBD variants harboring E484 alterations, including Beta and Gamma. Although 372 susceptibility to infection by viral variants is common to both vaccinated and convalescent 373 populations, particularly as antibody titers decrease over time (Israel et al., 2021; Levin et al., 374 2021) , our findings lead to the prediction that antibodies derived from infection may provide 375 somewhat decreased protection against virus variants compared to comparable concentrations of 376 antibodies stimulated by vaccination. 377 J o u r n a l P r e -p r o o f As additional variants of SARS-CoV-2 appear over time, individuals will acquire distinct 379 immunological histories depending on which vaccines they received and which viral variants 380 infected them. The idea that "imprinting" by a prior antigen exposure can shape, either positively 381 or negatively, the response to a subsequent variant is well established in studies of influenza 382 viruses, and has been implicated in birth-year differences in susceptibility to particular avian 383 influenza viruses (Gostic et al., 2016) . We find that prior vaccination with Wuhan-Hu-1- quickly decrease, although spike is still detectable in plasma in 63% of vaccinees one week after 457 the first dose. A practical finding in our study is that the detection of spike antigen in plasma 458 samples is impeded after 2 nd dose BNT162b2 vaccination, likely due to the formation of circulating 459 immune complexes of anti-spike antibodies and spike protein, masking the antigen epitopes of the 460 capture and detection antibodies that form the basis of antigen detection assays, similar to assay 461 interference that has been reported for other diseases (Bollinger et al., 1992; Lima et al., 2014; 462 Miles et al., 1993) . 

CoV-2 Wuhan-Hu-1 and viral variant RBD IgG responses are shown for Stanford individuals who 587 received BNT162b2 vaccination and for Wuhan-Hu-1-infected COVID-19 Stanford patient cohort 588 1 at different time points after vaccination / COVID-19 symptom onset. Box-whisker plots show 589 the interquartile range as the box and the whisker ends as the most extreme values within 1.5 times 590 the interquartile range below the 25% quantile and above the 75% quantile. Significance between 591 patient and vaccinee groups were tested with two-sided Wilcoxon rank sum test. *p < 0.05, **p < 592 0.01, ***p < 0.001. 

To study antibody responses after first, second, and third dose vaccination with BNT162b2, we 691 collected longitudinal blood and saliva samples from 59 vaccinees (29 were women, 27 were men, 692 samples were collected on day 0 before or immediately after the first vaccine dose. Individuals 694 received their second dose on day 21 and a third dose about 9 months after the prime. Blood sample 695 collection after prime vaccination was scheduled for days 1, 7, 21, 22, 28, and 42 with blood draws 696 ± one day from the assigned time point, or days 90, 120, or 210 ± 1 week from the assigned time 697 point. In addition, blood samples were collected on days 0 to 3, 7 to 10, 21, and 28 after the third 698 vaccine dose. Saliva samples were collected on day 42 after the first dose, as well as before, and 1 699 or 2, 3 or 4, 7, and 21 days after the third vaccine dose. Peripheral blood was collected in vacutainer 700 cell preparation tubes (CPTs) containing sodium citrate. Plasma was isolated and stored at -80°C. 701

Saliva was collected from study participants, centrifuged, and supernatants were stored at -80°C. 702

Institutional Review Board approved protocol IRB-55689. 704 705

Blood and saliva samples were collected between March and December 2020 from COVID-19 707 patients who reported to Stanford Healthcare-associated clinical sites. SARS-CoV-2 infection was 708 confirmed for all patients by RT-qPCR of nasopharyngeal swabs as described (Corman et al., 709 2020; Hogan et al., 2020) . Blood samples were collected in heparin-or EDTA-coated vacutainers. were from 20 women and 21 men, all between 2 and 92 years of age. SARS-CoV-2 genotyping 731 data were obtained using a multiplex, mutation-specific RT-qPCR targeting N501Y, E484K, and 732 L452R, as previously described (Wang et al., 2021) . Samples from the first multiplexed reaction 733 suspected to contain the Alpha variant were analyzed with a second confirmatory genotyping RT-734 qPCR assay to detect mutations encoding the N501Y amino acid change, as described (Dashdorj 735 et al., 2021a) . For in situ hybridization, manual methods were used as previously described (Cloutier et al., 2021) , Total lymphoid tissue and individual GCs were annotated as ROIs using QuPath. For each GC 856 ROI, the number of spots/clusters of RNAScope probe were detected using the QuPath subcellular 857 detection option per manufacture instructions. Our detection parameters were as follows: 858

Detection threshold = 0.6; split by intensity. Our split and cluster parameters were as follows: 859 expected spot size = 2 m 2 , min spot size = 2 m 2 , max spot size = 3 m 2 . 860 861

All antibodies used for CODEX were first screened, titrated, and validated by individual staining 863 on FFPE human tonsil tissue samples. Standard manual immunohistochemistry was used to cross-864 validate antibodies with the same, non-conjugated antibody clones listed in the key resource table. 865

Tissue preparation for CODEX was undertaken by obtaining eight-micron thick sections from 866 FFPE tissue blocks which were immobilized on charged square glass coverslips coated with 867 polylysine (Electron Microscopy Sciences, Hatfield, PA) prepared according to the manufacturer's 868 instructions. The coated glass coverslips were stained with a cocktail containing nucleotide-869 barcoded primary antibodies. The coverslips underwent nuclear staining (DAPI) and were loaded 870 on the stage of an automated inverted fluorescence microscope connected to the robotic fluidic 871 system known as CODEX (Akoya biosciences, Marlborough, MA). In addition to the nuclear stain, 872 fluorophore-tagged complementary nucleotide sequences (reporters) were used to iteratively 873 reveal three antibodies at a time per cycle. Two additional blank cycles at the beginning and at the 874 end of the antibody reveal cycles were added for purposes of subtraction of auto-fluorescence 875 background. Automated image acquisition, processing, segmentation, and fluidics exchange were 876 conducted using an Akoya CODEX instrument and CODEX driver software (Akoya biosciences) 877 (Black et al., 2021; Goltsev et al., 2018; Schürch et al., 2020) . Composite images providing 878 multiplex fluorescent signals of stained cell types, cellular niches, and tissue architecture were 879 captured using CODEX® MAV and FIJI software (Akoya biosciences). 880

Statistical tests were performed in R using base packages for statistical analysis and the ggplot2 883 package for graphics. Box-whisker plots show median (horizontal line), interquartile range (box), 884 and the end of the lower whisker representing the smallest observation greater than or equal to the 885 25% quantile minus 1.5 times the interquartile range, and the end of the upper whisker representing 886 the largest observation less than or equal to the 75% quantile plus 1.5 times the interquartile range. 887

In serological analyses where statistical significance was tested, significance was defined as: ***p 888 value < 0.001; **p value < 0.01; *p value ≤ 0.05. 889

For the principal component analysis (PCA) we log-transformed, calculated z-scores, and ran PCA 890 on MSD antibody concentration measurements or Wuhan-Hu-1/variant RBD IgG concentration 891 ratios from a reference time point after COVID-19 vaccination or SARS-CoV-2 infection using 892 were plotted for specimens with IgG binding above the cutoff for positive binding to Wuhan-Hu-907 1 RBD (Figures 3, 4 and S4) to avoid distortion of ratios by samples without specific binding. 908

Ratios of IgG binding to spike antigens were calculated in a similar manner ( Figure S4C Delta RBD binding level. Here, a ratio of one indicates even preference, while ratios greater than 914 one indicate preferential binding of Wuhan-Hu-1 over Delta. Each ratio is symmetric with its 915 inverse; for example, a Wuhan-Hu-1/Delta binding ratio of 4/5 indicates the same degree of 916 preference for Delta binding as the ratio 5/4 indicates for Wuhan-Hu-1 binding preference. We 917 then log-transformed the ratios, which sets the even preference level at zero, with positive values 918 corresponding to Wuhan-Hu-1 preference, and makes these values symmetric around zero (e.g., a 919 value of -0.2 indicates the same level of preference for Delta as +0.2 does for Wuhan-Hu-1 920 binding). Finally, we rescaled the negative and positive values separately to the ranges -100% to 921 0 and 0 to +100%. The resulting magnitudes are binding preferences relative to the maximum 922 binding preference observed for a particular variant, including data from individuals only exposed 923 to Wuhan-Hu-1 or individual variants. In particular, -100% refers to the maximum observed 924 binding preference towards Delta. We plotted the distributions of these binding preference levels 925

for BNT162b2 vaccinees without known prior SARS-CoV-2 infection, for Delta infection cases 926 with no recorded prior infection or vaccine exposure, and for Delta breakthrough infections 927 following Wuhan-Hu-1 wild-type vaccination. An example binding preference level of +30% for 928 a Delta breakthrough infection case suggests this individual is at 30% of the most imprinted state 929 for Wuhan-Hu-1 preference. A binding preference of -20% would instead suggest that, following 930 infection, this individual lost imprinting to Wuhan-Hu-1 and gained preference for binding the 931 CoV-2 concentrations show the interquartile range as the box and the whisker ends as the most 940 extreme values within 1.5 times the interquartile range below the 25% quantile and above the 75% 941 quantile. Comparisons between groups of previously SARS-CoV-2-infected (CoV-2+) versus non-942 infected individuals and female versus male were by the two-sided Wilcoxon rank sum test; 943 comparison between age groups (< 40; 40 to 60; > 60 years) was done using pairwise Wilcoxon 944 rank sum test with Bonferroni correction. *p < 0.05, **p < 0.01, ***p < 0.001. values within 1.5 times the interquartile range below the 25% quantile and above the 75% quantile. 983

Statistical test: pairwise Wilcoxon rank sum test with Bonferroni correction. *p < 0.05, **p < 0.01, 984 ***p < 0.001. 985

Individuals were classified as vaccinees who have not been previously exposed to SARS-CoV-2 986 (Vaccinees); outpatients (Outpt) and hospital admitted patients (Admit); intensive care unit (ICU) 987 patients, and those who died from their illness (Death). 988 (C) Box-whisker plots show anti-SARS-CoV-1 spike and anti-HCoV spike antibody responses in 989 plasma samples from individuals who received BNT162b2 prime (D0, n = 59 individuals), second 990 dose (D21, n =58 individuals) and third dose (around month 9, n = 36 individuals) vaccination. 991

Box-whisker plots show the interquartile range as the box and the whisker ends as the most extreme 992 values within 1.5 times the interquartile range below the 25% quantile and above the 75% quantile. 993 994 Figure S4 : Greater breadth of IgG binding to SARS-CoV-2 variant RBDs following 995

Representative CD21 immunohistochemistry of secondary (left) and primary (right) follicles 1035 of four autopsy patients who died of COVID-19 and two control autopsy patients

Original antigenic sin priming of 1040 influenza virus hemagglutinin stalk antibodies

Systems vaccinology of the BNT162b2 mRNA 1043 vaccine in humans

Efficacy and Safety of the mRNA

CoV-2 Vaccine

QuPath: Open source 1049 software for digital pathology image analysis

Arizona Study of Aging and Neurodegenerative 1052 Disorders and Brain and Body Donation Program

CODEX multiplexed tissue imaging with 1055 DNA-conjugated antibodies

Acid Dissociation Increases the Sensitivity of p24 Antigen Detection for the Evaluation of 1058

Antiviral Therapy and Disease Progression in Asymptomatic Human Immunodeficiency Virus-1059 Infected Persons

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine 1062 boosters in healthy adults: an interim analysis

Immune Memory Response After a Booster 1065 Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-1066 2)

Slow Delivery Immunization 1069

Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of 1070 Immunodominance

PDGFB RNA 1072 in situ hybridization for the diagnosis of dermatofibrosarcoma protuberans

Detection of 2019 novel coronavirus 1076 (2019-nCoV) by real-time RT-PCR

Direct comparison of antibody responses to 1079 four SARS-CoV-2 vaccines in Mongolia

Molecular and serological investigation of the 2021 COVID-19 case surge in 1082 Mongolian vaccinees

Evidence for antibody as a protective correlate for COVID-19 1085 vaccines

Germinal Center and Extrafollicular B Cell Responses 1087 in Vaccination

SARS-CoV-2 Neutralization with BNT162b2 1090 Vaccine Dose 3

Correlates of protection against symptomatic and asymptomatic 1093 SARS-CoV-2 infection

The Novel Severe Acute Respiratory Syndrome Coronavirus

Directly Decimates Human Spleens and Lymph Nodes. MedRxiv 2020.03.27

mRNA-based COVID-19 1099 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Immune correlates analysis of the 1102 mRNA-1273 COVID-19 vaccine efficacy clinical trial

Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed 1105 Imaging

Potent protection 1107 against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding 1111 domain that affect recognition by polyclonal human plasma antibodies

Antibodies elicited by mRNA-1273 vaccination bind more 1115 broadly to the receptor binding domain than do those from SARS-CoV-2 infection

SARS-CoV-2 variants, spike 1119 mutations and immune escape

Histomorphological 1121 patterns of regional lymph nodes in COVID-19 lungs

Normal human lymph node T follicular helper cells and germinal 1124 center B cells accessed via fine needle aspirations

The Omicron variant is highly 1128 resistant against antibody-mediated neutralization -implications for control of the COVID-19 1129 pandemic

Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope 1132 gene for detection of SARS-CoV-2

Large-scale study of antibody titer decay following 1135 BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Loss of Bcl-6-Expressing T 1138 Follicular Helper Cells and Germinal Centers in COVID-19

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health 1141 System Workforce

Neutralizing antibody levels are highly 1144 predictive of immune protection from symptomatic SARS-CoV-2 infection

B Cell Activation and Response Regulation 1147 During Viral Infections

Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody 1151 Generation

Germinal center responses to 1154 SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

Waning Immune Humoral Response to BNT162b2 Covid-1158 19 Vaccine over 6 Months

A simple heat dissociation method increases significantly 1161 the ELISA detection sensitivity of the nonstructural-1 glycoprotein in patients infected with 1162 DENV type-4

Induction of Robust B Cell Responses after Influenza 1165 mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ 1166 CXCR3+ T Follicular Helper Cells

Visualization of early events in mRNA 1169 vaccine delivery in non-human primates via PET-CT and near-infrared imaging

Antibody responses to SARS-CoV

Rapid Serologic Testing with Immune-Complex-Dissociated HIV 1176 p24 Antigen for Early Detection of HIV Infection in Neonates

Ultra-Sensitive Serial Profiling of SARS-CoV

Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients 1181 with Severe Disease

Nucleoside-modified mRNA vaccines induce 1184 potent T follicular helper and germinal center B cell responses

The variant gambit: COVID-19's next move

Safety and Efficacy of the BNT162b2 mRNA 1189

Covid-19 Vaccine

Antibody and B cell responses to SARS-CoV-2 infection 1191 and vaccination

Defining the features and duration of antibody 1194 responses to SARS-CoV-2 infection associated with disease severity and outcome

Safety and Efficacy of Single-Dose 1198

S Vaccine against Covid-19

Coordinated Cellular Neighborhoods Orchestrate 1201

Antitumoral Immunity at the Colorectal Cancer Invasive Front

SARS-CoV-2 mRNA vaccines induce persistent human 1204 germinal centre responses

Safety and efficacy of the ChAdOx1 1207 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised 1208 controlled trials in Brazil, South Africa, and the UK

Safety and Immunogenicity of

Based Covid-19 Vaccine Candidates

Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for 1214 Population-Level Variant Screening and Epidemiologic Surveillance

Immune imprinting and SARS-CoV-2 vaccine design

Extrafollicular B cell responses correlate 1220 with neutralizing antibodies and morbidity in COVID-19

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 1223 Variant Vaccine Booster

Recognition of the SARS-CoV-2 receptor 1225 binding domain by neutralizing antibodies

Original Antigenic Sin: How 1228 First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses

human IgG Meso Scale Discovery

Sulfo-tag conjugated anti-human IgM Meso Scale Discovery Cat#D21ADD-3

Sulfo-tag conjugated anti-human IgA Meso Scale Discovery Cat#D21ADE-3 ACE2 calibration reagent Meso Scale Discovery Cat#C01ADG-2

Meso Scale Discovery Cat#C00ADK-2

Anti-CD20 (clone SP32), for CODEX Abcam Cat#ab236434

Anti-CD3 (clone EP449E), for CODEX Akoya Biosciences Cat#4450027

Anti-CD21 (clone EP3093), for CODEX Akoya Biosciences Cat#4450027

clone IG191E/A8), for CODEX Biolegend Cat#648301

Anti-CD20 (clone L26), for IHC Dako Cat#M0755

Anti-CD3 (clone 2GV6), for IHC Ventana Cat#790-4341

Anti-CD21 (clone EP3093), for IHC Ventana Cat#760-4438

clone GL191E/A8), for IHC Ventana

Anti-PD-1 (clone NAT105), for IHC Cell-Marque Cat#315M-96

T62 (polyclonal) Sino Biological Cat#40143-T62

Anti-SARS-CoV-2 spike (clone 1A9) GeneTex Cat#GTX632604

Stanford individuals who received BNT162b2 vaccination and for Wuhan-Hu-1-infected COVID-999 19 Stanford patient cohort 2 at different time points after vaccination / COVID-19 symptom onset. 1000Box-whisker plots show the interquartile range as the box and the whisker ends as the most extreme 1001 values within 1.5 times the interquartile range below the 25% quantile and above the 75% quantile. 1002Significance between groups were tested with pairwise Wilcoxon rank sum test with Bonferroni 1003 correction. *p < 0.05, **p < 0.01, ***p < 0.001. 1004 (A) Anti-RBD IgG concentrations. 1005 (B) Ratios of anti-Wuhan-Hu-1 to variant RBD IgG concentration. 1006 (C) Anti-SARS-CoV-2 Wuhan-Hu-1 and viral variant spike IgG responses as anti-spike IgG 1007 concentrations (upper panels) and as ratios of anti-Wuhan-Hu-1 to variant spike IgG concentration 1008 (lower panels) are shown for Stanford individuals who received BNT162b2 vaccination and for 1009Wuhan-Hu-1-infected COVID-19 Stanford patient cohort 1 and 2 samples. Box-whisker plots 1010show the interquartile range as the box and the whisker ends as the most extreme values within 1.5 1011 times the interquartile range below the 25% quantile and above the 75% quantile. Significance 1012 between groups were tested with pairwise Wilcoxon rank sum test with Bonferroni correction. 1013 *p < 0.05, **p < 0.01, ***p < 0.001. color Co-detection by indexing (CODEX) immunofluorescence analysis for CD20 (red), CD3 1032 (blue), BCL6 (magenta) and CD21 (yellow) markers of B cells, T cells, GC B cells (